Clinical Trial

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

Study acronym: DREAM
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.
Protocol Amendment History 1 change
notable Trial sites reduced: 24 -> 21 locations 2026-05-12
Trial Details
NCT Number NCT07161388
Lead Sponsor AstraZeneca
Conditions Limited Stage Small-Cell Lung Cancer
Enrollment 200 participants
Start Date 2025-11-17
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04